Feedback / Questions
Truseltiq (infigratinib) - BridgeBio, Pfizer, Xediton Pharma
BridgeBio intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026.
(GlobeNewswire)
Oct 6, 2026
EMA filing
•
Genetic Disorders
https://www.globenewswire.com/news-release/2026/10/06/3375352/0/en/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-oral-infigratinib-for-children-with-achondroplasia.html
Oct 6, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next